April 22nd 2024
According to the company, OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene.
New dawn of GA management requires renewed attention to imaging
March 18th 2024It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.
PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
March 1st 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.
AAO 2023: AVD-104 and the results of the phase II/III part 1 SIGLEC trial
November 26th 2023Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.